EGFR-IN-194 

EGFR-IN-194 is a potent EGFR tyrosine kinase inhibitor with an IC₅₀ of 54.3 nM against human EGFR. EGFR-IN-194 induces apoptosis, inhibits migration in cancer cells, selectively promotes invasion in cancer cells, and exhibits antiproliferative effects across multiple cancer cell lines. EGFR-IN-194 can be used for the research of prostate adenocarcinoma, non-small cell lung carcinoma, breast carcinoma, chronic myeloid leukemia^[1].

EGFR-IN-194 (compound 24) (1-100 μM; 48 h) potently inhibits proliferation of PC-3, A549, MCF-7, and K562 cancer cells with IC₅₀ values of 3.18 μM, 9.69 μM, 43.51 μM, and 71.18 μM, respectively, while sparing NIH3T3 noncancerous cells^[1].
EGFR-IN-194 (5 μM; 24 h for PC-3; 10 μM; 24 h for A549) induces mitochondrial depolarization in PC-3 and A549 cells, and triggeres apoptosis in PC-3 and A549 cells^[1].
EGFR-IN-194 (5 μM; up to 48 h for PC-3; 10 μM; up to 48 h for A549) inhibited migration of PC-3 and A549 cells, as shown by reduced wound closure^[1].
EGFR-IN-194 (~18 h) promoted invasion of PC-3 cells and inhibited invasion of A549 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

504.62

C₂₈H₂₉FN₄O₂S

O=C(NC1=CC=C(F)C=C1)CSC2=NN=C(N2CC3=CC=CC=C3)COC4=C(C(C)C)C=CC(C)=C4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Bülbül B, et al. 1,2,4-Triazole-Acetamide Conjugates as hEGFR Inhibitors: Synthesis, Anticancer Evaluation, and In Silico Studies. Chem Biodivers. 2026;23(1):e03299.  [Content Brief]